|1.||Stone, Gregg W: 55 articles (06/2015 - 01/2004)|
|2.||Markman, Maurie: 53 articles (05/2015 - 02/2002)|
|3.||Serruys, Patrick W: 39 articles (01/2015 - 02/2003)|
|4.||Scambia, Giovanni: 37 articles (07/2015 - 03/2002)|
|5.||Socinski, Mark A: 37 articles (05/2015 - 07/2002)|
|6.||Hortobagyi, Gabriel N: 35 articles (01/2015 - 05/2002)|
|7.||Perez, Edith A: 30 articles (07/2015 - 05/2002)|
|8.||Fountzilas, G: 30 articles (01/2013 - 02/2000)|
|9.||Duan, Zhenfeng: 29 articles (10/2015 - 01/2003)|
|10.||Zhang, Qiang: 28 articles (12/2015 - 01/2003)|
01/01/2013 - "It has proven resistant in clinical trials to chemotherapeutic agents such as paclitaxel that are highly effective in vitro, presumably because of impaired drug delivery across the tumor's blood-brain barrier (BBB). "
01/01/2014 - "Compared to treatment with paclitaxel alone, treatment with combination of paclitaxel and ETA achieved significant reduction in volume and weight of HeLa tumors (p<0.05), and remarkable inhibition to the growth of KB-3-1 tumors (p<10⁻⁶). "
01/01/2013 - "All the target compounds showed improved anti-proliferative activity against a panel of human cancer cell lines and the most effective compound 12j was more potent than positive control Taxol in K562 and Bel-7402 cells with IC(50) values of 0.39 μM and 1.39 μM, respectively. "
07/14/2011 - "The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. "
01/01/2011 - "Paclitaxel is highly effective in the treatment of many cancers in humans, but cannot be routinely used in dogs as currently formulated due to the exquisite sensitivity of this species to surfactant-solubilizing agents. "
|2.||Breast Neoplasms (Breast Cancer)
09/01/2005 - "Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks."
01/01/1993 - "Taxol is an important new antitumor agent with demonstrated efficacy in ovarian and breast cancer. "
01/01/2015 - "The restoration of Bak expression would be therapeutically beneficial for Taxol resistant breast cancer patients. "
05/01/2010 - "EC followed by weekly paclitaxel therapy was effective for the locally advanced ulcerative breast tumor, and significantly improved QOL in this patient with Stage III C advanced breast cancer."
01/01/2007 - "It is therefore concluded that paclitaxel in combination with seal oil demonstrated enhanced cytotoxicity and apoptosis in MCF-7 and MDA-MB-231 cells compared to paclitaxel alone, and the use of seal oil may be beneficial in the treatment of breast cancer."
|3.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2009 - "Paclitaxel is used in the first line treatment of ovarian cancer, but acquired resistance represents the most important clinical problem and a major obstacle to a successful therapy. "
09/01/2007 - "Both times, the paclitaxel dramatically improved the ovarian cancer. "
03/01/2004 - "Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian cancer. "
02/15/1995 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. "
08/01/1998 - "The correlation between high BAX levels and improved clinical outcome suggests that an intact apoptotic pathway is an important determinant of chemoresponsiveness in ovarian cancer patients who receive paclitaxel."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2004 - "We believe that using paclitaxel in concurrent chemoradiotherapy regimens may be effective in patients with unresectable, locoregionally advanced non-small cell lung cancer."
12/01/2001 - "Paclitaxel administered as a weekly 1-h infusion at a dose of 90 mg/m(2) is a safe and effective therapy for elderly patients with advanced non-small cell lung cancer. "
04/01/1999 - "Several studies have been conducted to assess the safety and efficacy of paclitaxel plus radiation therapy in patients with non-small cell lung cancer (NSCLC) and to assess whether the radiosensitization demonstrated by paclitaxel in vivo can translate into clinical benefit. "
01/01/2000 - "To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). "
10/01/2012 - "In the five NSCLC (non small cell lung cancer) trials, the summary effect revealed a better response rate with weekly paclitaxel (odds ratio: 1.24, p=0.042). "
10/15/2001 - "Treatment of ovarian carcinomas with the antimitotic antitumor drug paclitaxel is highly efficacious. "
04/01/2006 - "The significant efficacy of (90)Y-hu3S193 and paclitaxel CMRIT at low radiation doses in this model of breast carcinoma indicates its therapeutic potential and warrants further investigation into this promising therapeutic approach."
02/01/2002 - "NMP-1 and HEY models have significant value in establishing the efficacy of candidate agents, which might address Taxol-resistant human ovarian carcinoma. "
04/01/2014 - "Using optimized inoculation densities and schedules, treatment with paclitaxel was effective in gastric carcinoma cell lines, SNU-16 and SNU-484, but not in SNU-668. "
05/01/2010 - "Paclitaxel monotherapy is likely to be effective in treating sarcomatoid carcinoma of the thymus."
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)